BTK inhibitor therapy for patients with CLL/SLL- treatment barriers BTK inhibitors in CLL/SLL & adverse events- Dr. Javier Pinilla Ibarz

[lankisterguy]

This video was intended for medical professionals and is delivered as a fast paced recap of current state of the art in CLL. IMO experienced CLL patients that have moderate command of Med-speak lingo may find it useful.

-

If you are new to CLL you may want to read and follow all the links included in this Pinned Post: healthunlocked.com/cllsuppo...

instead or first.

-

Len

-

Detailed description: naccme.com/program/21-moc-5...

Video naccme.com/node/37439/cours...

-

We are excited to announce this new webcast on managing adverse events associated with BTK inhibitor therapy for patients with CLL/SLL.

-

This accredited, on-demand activity features a presentation that discusses treatment barriers associated with the use of BTK inhibitors in CLL/SLL including adverse events and potential implications due to the combination of targeted therapies.

-

Learning Objectives

After participating in this activity, learners should be better able to:

-

Describe factors that influence first- and second-line therapeutic sequencing in CLL/SLL, as well as current recommendations from appropriate treatment guidelines

-

Evaluate the most recent clinical efficacy and safety data surrounding BTK inhibitors for the treatment of CLL/SLL

-

Assess treatment barriers associated with use of BTK inhibitors in CLL/SLL including adverse events and potential implications due to the combination of targeted therapies

-

Implement strategies through collaboration with a multidisciplinary care team for the optimal management of adverse events associated with BTK inhibitor therapy

-

Lisa Nodzon, PhD, ARNP, AOCNP

Advanced Registered Nurse Practitioner

Department of Malignant Hematology

Moffitt Cancer Center

Tampa, Florida

-

Javier Pinilla Ibarz, MD, PhD

Senior Member, Head of the Lymphoma Section

Director of Immunotherapy

Malignant Hematology Department

Moffitt Cancer Center

Tampa, Florida

[jimvan]

Thanks for posting this. I found it fascinating and enlightening personally.

[db601]

Len,Well worth the hour of concentration - post caffeine.

Your links worked well. Thank you so much for sharing these teaching opportunities. The therapy landscape is getting complicated and filled with choices - not always directly benefiting the profile of the individual patient.

I am happy for the research and drugs emerging to address our needs and disease. I am more convinced of the personal accountability to keep ourselves informed and proactive in our treatments.

Basic protocols are no longer enough to monitor the complexities of CLL. In my case, Molecular genomics and NGS - Next Generation Sequencing requests must be added to BM scripts to reveal the entire picture with the latest tools available.

Any tumor sample from biopsies or surgery , must be sequenced to know what emerging variants are changing the landscape.

Ex: my family has an ATM mutation - in my case now showing a CHEK2 variant in the recent DCIS tumor - cancer #5 - removed at 2 cm - no watch and wait!

Result - increasing surveillance and being committed to early intervention. (CHEK2 is a non BRCA1 breast cancer - 1 of 9 predominant breast cancer mutations)

This may also influence the choice of CLL drug in the future. I have been on Ibrutinib for 7 years -

now at 70 mg.

Getting all of the providers onboard for frequent surveillance, NGS and early intervention is another story. Mental gymnastics as a personal patient advocate are exhausting and finding someone well versed in *genetics and Hem/onc* is difficult. The younger physicians are more amenable to this field being integrated in test requests. Costs are always a factor. This is the fight to get what you need.

It makes a difference.

My mantra:

Frequent surveillance and early intervention.

And definitely - no *watch and wait* -

Thanks, Len and all the administrators for providing the remarkable opportunities to add to

our knowledge.

Diana